JP7781059B2 - ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用 - Google Patents

ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用

Info

Publication number
JP7781059B2
JP7781059B2 JP2022529505A JP2022529505A JP7781059B2 JP 7781059 B2 JP7781059 B2 JP 7781059B2 JP 2022529505 A JP2022529505 A JP 2022529505A JP 2022529505 A JP2022529505 A JP 2022529505A JP 7781059 B2 JP7781059 B2 JP 7781059B2
Authority
JP
Japan
Prior art keywords
group
membered
general formula
mixture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022529505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502458A (ja
JP2023502458A5 (https=
Inventor
心 李
懐徳 董
東棟 白
峰 賀
維康 陶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of JP2023502458A publication Critical patent/JP2023502458A/ja
Publication of JP2023502458A5 publication Critical patent/JP2023502458A5/ja
Application granted granted Critical
Publication of JP7781059B2 publication Critical patent/JP7781059B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022529505A 2019-11-21 2020-11-20 ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用 Active JP7781059B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911147956 2019-11-21
CN201911147956.3 2019-11-21
CN202010837381.4 2020-08-19
CN202010837381 2020-08-19
PCT/CN2020/130326 WO2021098811A1 (zh) 2019-11-21 2020-11-20 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2023502458A JP2023502458A (ja) 2023-01-24
JP2023502458A5 JP2023502458A5 (https=) 2023-11-30
JP7781059B2 true JP7781059B2 (ja) 2025-12-05

Family

ID=75981069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529505A Active JP7781059B2 (ja) 2019-11-21 2020-11-20 ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用

Country Status (11)

Country Link
US (1) US12559488B2 (https=)
EP (1) EP4063363A4 (https=)
JP (1) JP7781059B2 (https=)
KR (1) KR20220103987A (https=)
CN (5) CN120004887A (https=)
AU (1) AU2020386587A1 (https=)
BR (1) BR112022008000A2 (https=)
CA (1) CA3159376A1 (https=)
MX (1) MX2022005985A (https=)
TW (1) TW202128690A (https=)
WO (1) WO2021098811A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024521129A (ja) * 2021-05-21 2024-05-28 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ピラゾロヘテロアリール誘導体の薬学的に許容される塩及びその結晶形

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
TW202220993A (zh) * 2020-08-07 2022-06-01 香港商德琪研發有限公司 Atr抑制劑及其用途
WO2022135560A1 (en) * 2020-12-25 2022-06-30 Impact Therapeutics (Shanghai) , Inc Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof
WO2023109883A1 (zh) * 2021-12-15 2023-06-22 上海翊石医药科技有限公司 一类芳杂环取代的化合物及其制备方法和用途
WO2024109727A1 (zh) * 2022-11-21 2024-05-30 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐的结晶形式
CN119143753B (zh) * 2023-06-14 2026-01-02 石药集团中奇制药技术（石家庄）有限公司 一种杂环类抗肿瘤化合物的盐及其晶型

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500277A (ja) 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
JP2016516706A (ja) 2013-03-12 2016-06-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
WO2018153970A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
JP2019508384A (ja) 2016-01-14 2019-03-28 バイエル・ファルマ・アクティエンゲゼルシャフト ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
WO2020049017A1 (en) 2018-09-07 2020-03-12 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
US20110053923A1 (en) * 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
US20190000850A1 (en) 2015-02-09 2019-01-03 The Regents Of The University Of California Combination cancer therapy
WO2017118734A1 (en) 2016-01-08 2017-07-13 The Institute Of Cancer Research: Royal Cancer Hospital Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
US11730734B2 (en) 2016-09-12 2023-08-22 University Of Florida Research Foundation, Incorporated Use of ATR and Chk1 inhibitor compounds
EP3679041B1 (en) 2017-09-08 2022-07-06 Newave Pharmaceutical Inc. Substituted pyrrolopyridines as atr inhibitors
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500277A (ja) 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
JP2016516706A (ja) 2013-03-12 2016-06-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
JP2019508384A (ja) 2016-01-14 2019-03-28 バイエル・ファルマ・アクティエンゲゼルシャフト ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
WO2018153970A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
WO2020049017A1 (en) 2018-09-07 2020-03-12 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
JP2021536473A (ja) 2018-09-07 2021-12-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ５−モルホリン−４−イル−ピラゾロ［４，３−ｂ］ピリジン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024521129A (ja) * 2021-05-21 2024-05-28 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ピラゾロヘテロアリール誘導体の薬学的に許容される塩及びその結晶形

Also Published As

Publication number Publication date
JP2023502458A (ja) 2023-01-24
CN114423760A (zh) 2022-04-29
CN120004886A (zh) 2025-05-16
WO2021098811A1 (zh) 2021-05-27
KR20220103987A (ko) 2022-07-25
EP4063363A1 (en) 2022-09-28
TW202128690A (zh) 2021-08-01
AU2020386587A1 (en) 2022-06-02
BR112022008000A2 (pt) 2022-07-12
CN120004872A (zh) 2025-05-16
EP4063363A4 (en) 2023-11-29
CN120004888A (zh) 2025-05-16
CA3159376A1 (en) 2021-05-27
US20230018728A1 (en) 2023-01-19
CN120004887A (zh) 2025-05-16
MX2022005985A (es) 2022-06-17
US12559488B2 (en) 2026-02-24
CN114423760B (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
JP7781059B2 (ja) ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用
WO2021203768A1 (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
RU2717577C2 (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
CN117177971A (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN114149423B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN120230123A (zh) 稠环类化合物、其制备方法及其在医药上的应用
KR20210146956A (ko) 피롤로헤테로고리형 유도체, 이의 제조 방법, 및 의약에서 이의 응용
CN113825757B (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
CN113518779B (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
CN118339157A (zh) 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN120535536A (zh) 稠合杂芳基类化合物、其制备方法及其在医药上的应用
CN108779100B (zh) 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用
CN112996783A (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN115867552B (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN114790205A (zh) 氘代吡唑并吡啶类化合物、其制备方法及其在医药上的应用
JP2023536442A (ja) オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用
CN113004303A (zh) 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
HK40070277B (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN114478447B (zh) 苯并含氧环类衍生物、其制备方法及其在医药上的应用
HK40070277A (en) Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof
CN110964034B (zh) 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
CN114656486B (zh) 嘌呤酮类化合物、其制备方法及其在医药上的应用
TW202140474A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251125

R150 Certificate of patent or registration of utility model

Ref document number: 7781059

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150